Clinical trials
Solid Tumor clinical trials
Below are recruiting solid tumor clinical trials, each written for real people, not researchers. We’re tracking 1,689 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05203172RecruitingPhase 4
Continue encorafenib and binimetinib after prior trial benefit
This study lets people who previously took encorafenib and binimetinib continue those same medicines if they are benefiting and side effects are not severe. It’s meant to help participants stay on treatment safely while the original trial is completed.
Phoenix, ArizonaAges 18 years+ - NCT05151718Recruiting
Study of ependymoma treatment resistance in children
This trial looks at why ependymoma can resist (be harder to treat) after radiation or treatment. It studies children who are already being followed in specific existing programs, which may help researchers find better treatment approaches in the future.
ToulouseAges Up to 25 years - NCT05098847RecruitingPhase 2
Freezing liver tumors plus anti-cancer drugs for spread cancer
This trial tests whether freezing (cryoablation) liver metastases works better when combined with immunotherapy (sintilimab) and a targeted pill (lenvatinib). It’s for people whose cancer has spread to the liver and has not responded to earlier treatments.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT02421380Recruiting
Tests how repeatable a special MRI scan is for tumors
This study checks whether a specialized MRI using injected “hyperpolarized pyruvate” gives consistent tumor images when repeated. It may help future patients by improving how reliably this scan can measure tumors.
Montvale, New JerseyAges 21–90 - NCT05620732Recruiting
CAR-T treatment for advanced stomach or pancreatic cancer
This trial tests a customized immune-cell treatment (CAR-T) for advanced stomach or pancreatic cancer that cannot be removed by surgery. It aims to use cells engineered to target a specific tumor marker to shrink cancer or slow its growth.
Shenzhen, GuangdongAges 18–75 - NCT04932525Recruiting
Cancer profiling study for adults with eligible tumors
This study helps doctors better understand your cancer by doing tumor/cancer profiling as part of research. If you qualify, your participation may help improve how cancers are studied and matched with future treatments.
Villejuif, Val de MarneAges 18 years+ - NCT05223608Recruiting
Study of people starting immunotherapy for solid tumors
This study follows people who are starting their first immune “checkpoint” treatment for a solid cancer. It collects clinic information and lab results to understand how patients respond and what factors matter most.
Lille, Hauts-de-FranceAges 18 years+ - NCT04495296RecruitingPhase 1/Phase 2
TST001 for advanced or metastatic solid tumors
This Phase 1/2 study tests TST001, and sometimes a combination with other cancer medicines, to see how safe it is and how well it may work in advanced or metastatic solid tumors. You might be eligible if you have certain tumor types and lab/health requirements, and if your tumor tissue shows specific marker results (depending on the study part).
Bengbu, AnhuiAges 18 years+ - NCT04260269Enrolling by invitation
Testing a switch to a different chemotherapy type after heart side effects
This study looks at whether people with solid tumors who develop heart-related side effects during a fluoropyrimidine chemotherapy can safely switch to a different fluoropyrimidine. It aims to see if the new option is feasible to use again when the first one caused cardiotoxicity.
OdenseAges 18 years+ - NCT06262919Recruiting
Monitoring safety of Tafinlar/Mekinist for BRAF-positive tumors
This study tracks the safety of the combination therapy Tafinlar and Mekinist in people with advanced or returning solid tumors that have a BRAF mutation, except for colorectal cancer. It aims to make sure the treatment is safe in the real world.
Nagakute, Aichi-kenAges 6–99 - NCT05982080RecruitingPhase 1
FP002 for advanced solid tumors
This trial tests a new drug called FP002 for people with advanced solid tumors that have not responded to or cannot have standard treatments. It aims to see if the drug is safe and can help shrink or control the cancer.
Xiamen, FujianAges 18 years+ - NCT00992303Recruiting
Collecting tissue samples during radiation for people with cancer
This study collects tissue samples from people with cancer while they are getting radiation therapy. It also includes healthy participants, to help researchers compare samples and better understand cancer and treatment.
Dallas, TexasAges 18 years+ - NCT05701150Recruiting
Connects advanced solid-tumor patients to tumor gene data
This trial builds a large database using your existing tumor genetic test results (DNA and/or RNA). It may help researchers better understand advanced cancers and use gene patterns to guide future care.
Freiburg im Breisgau, Baden-WurttembergAges 18 years+ - NCT06466070Enrolling by invitation
Robotic surgery to remove lung metastases
This trial uses robotic-assisted surgery to remove cancer that has spread to the lung from another part of the body. It is for people whose original cancer is under control and who are healthy enough for surgery.
Rome, Italy / RomeAges 18 years+ - NCT06429891Recruiting
Nuclear probe for early gastric cancer detection
This trial uses a special radioactive probe to find gastric cancer cells during imaging. It may help doctors see tumors more clearly and catch the disease earlier.
Beijing, Beijing MunicipalityAges 18–70 - NCT01620372Recruiting
Study of heart and health after solid childhood cancers
This study follows people in France who had a solid (not leukemia) childhood cancer before age 19 between 1942 and 1999. It helps researchers understand long-term effects after cancer and how to better support survivors.
AmiensAges Up to 18 years - NCT06408688RecruitingPhase 4
Mistletoe extract added to immunotherapy for advanced solid tumors
This trial tests whether adding mistletoe extract (Iscador) to standard immunotherapy can make the treatment safer and boost the immune system's response against advanced solid tumors (excluding skin cancer). If you are already receiving or about to start a checkpoint inhibitor, this study may help understand if the combination works better.
BadenAges 18 years+ - NCT06816992RecruitingPhase 1
ORIC-114 with amivantamab for EGFR exon 20 insertion lung cancer
This trial tests an experimental pill (ORIC-114) combined with a targeted injection (amivantamab) for a specific type of non-small cell lung cancer that has an EGFR exon 20 insertion mutation. It aims to see if the combination shrinks tumors or delays growth.
New York, New YorkAges 18 years+ - NCT07117461Recruiting
Distress screening program for newly diagnosed cancer patients
This study tests a program that screens for distress and connects you to support services shortly after a cancer diagnosis. It aims to improve emotional well-being and quality of care.
New York, New YorkAges 18 years+ - NCT02806388Recruiting
Molecular testing to match you to the right cancer trial
This trial uses a tissue sample from your tumor to look for specific molecular changes, then helps match you to available clinical trials. It may help by directing treatment research toward tumors most likely to benefit.
SingaporeAges 12 years+ - NCT06719362RecruitingPhase 1
Testing a new cancer drug alone and with other therapies
This trial tests an experimental drug called M3T01, either alone or combined with pembrolizumab and other standard treatments, for people with advanced solid tumors or glioblastoma. The goal is to see if it is safe and effective.
Portland, OregonAges 18 years+ - NCT07381829RecruitingPhase 1
HC010 plus chemotherapy for advanced lung cancer
This trial tests an experimental drug called HC010 combined with chemotherapy for people with advanced lung cancer, including certain types of non-small cell or small cell lung cancer. It aims to see if the combination is safe and effective.
Guangzhou, GuangdongAges 18–75 - NCT06769685Enrolling by invitation
Platelet-boosting drug for solid tumor patients with low platelets
This trial tests if combining two platelet-raising drugs (TPO and a TPO receptor agent) can help patients with solid tumors who have very low platelets after cancer treatment. It aims to prevent or treat severe platelet drops.
Jinhua, ZhejiangAges 18 years+ - NCT07231120RecruitingPhase 1
Testing SXRN injection for cancer-related weight loss
This trial tests a new injection called SXRN for people with advanced cancer who have lost weight and appetite (cancer cachexia). The goal is to see if it is safe and might help improve weight and appetite.
Beijing, Beijing MunicipalityAges 18–75
Hear when a new Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for solid tumor?
- Yes. Clin2 currently lists 1,689 recruiting solid tumor studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a solid tumor trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a solid tumor trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.